Table 7.

Some of the recent clinical experience with MammoSite [29]

Institution	APBI technique	No. Of cases	Follow-up (years)	Inclusion criteria and definition of target	Ipsilateral breast recurrence
American Society of Breast Surgeons, MammoSite Breast Brachytherapy Trial [59–64]	34 Gy/10 fr/5 d	1255	2.5	> 45 years, T6 2 cm, N0, negative margins, ductal only, applicator placement < 10 weeks postoperative, cavityP3 cm in one dimension, no EIC,	2 years – 1.11%, 3 years – 1.79%
Texas Cancer Clinic San Antonio [65]	34 Gy/10 fr/5-7 d	67	1.1	≥ 45 years, T < 3 cm, N0, negative margins, lumpectomy cavity 3-6 cm	NA
Kaiser Pernamente Los Angeles Medical Center [66, 67]	34 Gy/10 fr/5-7 d	51	1.3	≥ 45 years, T6 2 cm, N0, ductal only, negative margins	0
Rush University Medical Center, Chicago [68, 69]	34 Gy/10 fr/5-7 d	78	2.2	≥ 45 years, T < 3 cm, N0, negative margins	7.1%
Medical University of South Carolina [70]	32 Gy/10 fr/5-7 d	37 (7 with DCIS)	0.5	any age, pTis-pT2N1, negative margins	NA
Tufts New England [71, 72]	34 Gy/10 fr/5-7 d	38	1.4	any age, T < 3 cm, ductal and DCIS, N0 (solitary nodal micrometastasis accepted), negative margins > 1 mm	NA
European MammoSite trial [73, 74]	34 Gy/10 fr/5-7 d	28	1.2	≥ 60 years, T ≤ 2 cm, ductal only, grade 1/2, margins > 5 mm, ER +, balloon-skin distance > 7 mm, lumpectomy cavity > 3 cm, no EIC	0

EIC – extensive intraductal component; DCIS – ductal carcinoma in situ; ER – estrogen receptor; PR – progesterone receptor; N/A – data not available; d – days; fr – fractions